Daily FNArena News - Australia

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements

Pro Medicus’ growth story is far from over. How should investors deal with the valuation challenge of one of Australia’s premium growth companies?

Independent Investment Research updates developments in Australia’s listed investment trust and provides comparative data

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements

A Christmas special with a deep dive into why Generative Ai remains a growing tour de force for both enterprises, consumers, economies and investors. What’s in store for 2025?

Rio Tinto’s investor seminar outlined near, medium and long term growth plans with a focus on copper, lithium and, to a lesser extent, its primary iron ore business

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements

Collins Foods’ navigation of a challenged consumer positions the company for an earnings rebound with cost deflation offering 2025 tailwinds

Australian equities underperformed US peers in November but outperformed most of the rest of the world, led by Technology and Financials